直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Teva Pharmaceuticals International GmbH

Eli Lilly and Company

Successfully represented Eli Lilly in defensive patent litigation and in offensive inter partes reviews (IPRs) regarding products related to the treatment of migraines.

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, 1:21-cv-10954, D. Mass., Judge Burroughs

Related Professionals

Mark J. Feldstein, Ph.D.
Partner
Washington, DC
+1 202 408 4092
Email
Alissa K. Lipton
Partner
Washington, DC
+1 202 408 4293
Email
Kenneth S. Guerra
Associate
Washington, DC
+1 202 408 4124
Email

Related Practices

Global IP Enforcement, Litigation, and Trials

Patent Litigation and Trials

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Life Sciences

Pharmaceutical

Biotechnology

Biologics

Related Experiences

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Eli Lilly and Company

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

Eli Lilly and Company

Eli Lilly and Company v. Teva Pharmaceuticals International

Eli Lilly and Company

Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.

Eli Lilly and Company

Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.

Biogen International GmbH

Grünenthal GmbH v. Teva Pharmaceuticals

Grünenthal GmbH

Eli Lilly and Company v. Actavis Labs. UT Inc.

Eli Lilly and Company

IntelGenX Corporation v. Eli Lilly and Company; ICOS Corporation

Eli Lilly and Company; ICOS Corporation

When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan

Eli Lilly and Company

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP